Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track SPRO with free AI briefings, catalyst countdowns, and dilution alerts.

SPRO

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$56.1M Cash on Hand

CF+ Cash Runway

3.6% Short Interest

🧪 Upcoming Trial Catalysts

2026-05-13 · fda_pdufa — PDUFA Date Mentioned in 8-K Filing
2026-03-26 · fda_pdufa — PDUFA Date Mentioned in 8-K Filing
2025-04-22 · Phase 1 — Results Expected — A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydro
2025-01-27 · Phase 3 — Results Expected — A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipen
2024-10-08 · Phase 2 — Results Expected — A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as
2024-02-09 · Phase 1 — Results Expected — A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plas

📊 Drug Pipeline

Drug	Indication	Phase	Status
TBP-PI-HBr	Urinary Tract Infection	PHASE3	COMPLETED
Dummy Infusion	Urinary Tract Infection	PHASE3	COMPLETED
Dummy Tablets	Complicated Urinary Tract Infection	PHASE3	COMPLETED
Ertapenem	Complicated Urinary Tract Infection	PHASE3	COMPLETED
TBPM-PI-HBr	Complicated Urinary Tract Infection	PHASE3	COMPLETED
Imipenem-cilastatin	Urinary Tract Infection	PHASE3	COMPLETED
SPR720 500 mg	Nontuberculous Mycobacterial Pulmonary Disease (NT	PHASE2	COMPLETED
SPR720 1000 mg	Nontuberculous Mycobacterial Pulmonary Disease (NT	PHASE2	COMPLETED
SPR720	Mycobacterium Avium Complex	PHASE2	TERMINATED
Open-label Standard of Care	Mycobacterium Avium Complex	PHASE2	TERMINATED

💰 Cash Runway & Dilution Risk

SPRO holds $56.1M in cash and its operations are currently cash-flow neutral or positive. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for SPRO free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-05-06	Rajavelu Esther	Sale	$2.5M
2026-02-09	Keutzer Timothy	Sale	$1.8M
2026-02-09	Rajavelu Esther	Sale	$2.5M
2026-02-09	Rajavelu Esther	Sale	$2.4M
2026-02-05	Keutzer Timothy	Purchase	$0

Get the full SPRO picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for SPRO and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z